Clinical applications of proteomics: Proteomic pattern diagnostics

被引：94

作者：

Petricoin, EF

Paweletz, CP

Liotta, LA

机构：

[1] US FDA, FDA NCI Clin Proteom Program, Div Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA

[2] NCI, FDA NCI Clin Proteom Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA | 2002年 / 7卷 / 04期

关键词：

proteomics; patterns diagnostics; nipple fluid; breast cancer; mass spectrometry; genetic algorithms;

D O I：

10.1023/A:1024042200521

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Clinical proteomics is an exciting new subdiscipline of proteomics that involves bedside application of proteomic technologies. A new and potentially revolutionary technology and approach for early disease detection, surveillance, and monitoring is proteomic pattern diagnostics. Using this approach, high throughput mass spectrometry generates a proteomic fingerprint of a given body fluid, such as serum or nipple fluid aspirants (NAF), in less than 30 s. This information archive is then used by new types of bioinformatic pattern recognition algorithms to identify patterns of protein changes that can discriminate cancer from healthy and unaffected individuals. This entire process can take place in less than a minute and requires only a droplet of blood, NAF, or ductal lavage washings. The new concept that is introduced by this platform is that the underlying identities of the proteins that comprise the patterns are not known and do not need to be known; the pattern itself becomes the diagnostic.

引用

页码：433 / 440

页数：8

共 42 条

[1]

Adam BL, 2001, PROTEOMICS, V1, P1264, DOI 10.1002/1615-9861(200110)1:10<1264::AID-PROT1264>3.0.CO

[2]

2-R

[3]

Adam BL, 2002, CANCER RES, V62, P3609

[4]

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[5]

An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers [J].

Ball, G ;

Mian, S ;

Holding, F ;

Allibone, RO ;

Lowe, J ;

Ali, S ;

Li, G ;

McCardle, S ;

Ellis, IO ;

Creaser, C ;

Rees, RC .

BIOINFORMATICS, 2002, 18 (03) :395-404

[6]

Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer [J].

Carter, D ;

Douglass, JF ;

Cornellison, CD ;

Retter, MW ;

Johnson, JC ;

Bennington, AA ;

Fleming, TP ;

Reed, SG ;

Houghton, RL ;

Diamond, DL ;

Vedvick, TS .

BIOCHEMISTRY, 2002, 41 (21) :6714-6722

[7]

Cazares LH, 2002, CLIN CANCER RES, V8, P2541

[8]

Ten-year risk of false positive screening mammograms and clinical breast examinations [J].

Elmore, G ;

Barton, MB ;

Moceri, VM ;

Polk, S ;

Arena, PJ ;

Fletcher, SW .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (16) :1089-1096

[9]

Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR [J].

Evron, E ;

Dooley, WC ;

Umbricht, CB ;

Rosenthal, D ;

Sacchi, N ;

Gabrielson, E ;

Soito, AB ;

Hung, DT ;

Ljung, BM ;

Davidson, NE ;

Sukumar, S .

LANCET, 2001, 357 (9265) :1335-1336

[10]

FISHER B, 1992, CANCER RES, V52, P2371

← 1 2 3 4 5 →